Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
Clinical trial NCT07231445 · RECRUITING
Trial details
- NCT number
- NCT07231445
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-21
- Primary completion
- 2028-12-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.